Wall St futures flat amid US-China trade jitters; bank earnings in focus
Fulgent Genetics NASDAQ:FLGT President and COO Jian Xie sold 1,128 shares of common stock on September 3, 2025, for approximately $24,846. The sale comes as the stock trades near its 52-week high of $23.56, having gained over 44% in the past six months. The shares were sold in multiple transactions at prices ranging from $21.92 to $22.175.
Following the transaction, Xie directly owns 364,121 shares of Fulgent Genetics. Xie also indirectly owns 220,816 shares through The Hsieh Family Dynasty Trust. The $683 million market cap company maintains a strong balance sheet with more cash than debt, though InvestingPro analysis indicates the stock may be overbought at current levels. For deeper insights into Fulgent’s financial health and valuation metrics, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro.
In other recent news, Fulgent Genetics reported its Q2 2025 earnings, revealing a revenue of $81.8 million, which exceeded the forecasted $76.21 million. However, the company reported an earnings per share (EPS) of $0.07, which fell short of the anticipated EPS of $-0.18. This earnings announcement highlights a significant revenue achievement despite the EPS miss. Additionally, UBS upgraded Fulgent Genetics’ stock rating from Neutral to Buy, raising the price target to $30.00 from $20.00. UBS cited potential growth in Fulgent’s Precision Diagnostics segment, which accounts for about 60% of total sales. The investment bank noted opportunities for share gains in a more favorable reimbursement environment. These developments suggest a positive outlook from analysts regarding the company’s future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.